NEUROCRINE BIOSCIENCES INC Net Income (Loss) Available to Common Stockholders, Basic
NEUROCRINE BIOSCIENCES INC (NBIX) reported Net Income (Loss) Available to Common Stockholders, Basic of $144.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $144.40M, a 34.33% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $197.90M, a 2405.06% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $153.70M, a 49.08% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $209.50M, a 61.40% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for fiscal 2025 was $478.60M, a 40.23% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for fiscal 2024 was $341.30M, a 36.68% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for fiscal 2023 was $249.70M, a 61.62% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC net income (loss) available to common stockholders, basic for fiscal 2022 was $154.50M, a 72.43% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.40M 10-Q · filed 2026-07-31 | $342.30M 10-Q · filed 2026-07-31 | $496.00M derived: sum of 3 quarters · filed 2026-07-31 | $705.50M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $197.90M 10-Q · filed 2026-05-05 | $351.60M derived: sum of 2 quarters · filed 2026-05-05 | $561.10M derived: sum of 3 quarters · filed 2026-05-05 | $668.60M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $153.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $363.20M derived: sum of 2 quarters · filed 2026-02-11 | $470.70M derived: sum of 3 quarters · filed 2026-07-31 | $478.60M 10-K · filed 2026-02-11 |
| 2025-09-30 | $209.50M 10-Q · filed 2025-10-28 | $317.00M derived: sum of 2 quarters · filed 2026-07-31 | $324.90M 10-Q · filed 2025-10-28 | $428.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $107.50M 10-Q · filed 2026-07-31 | $115.40M 10-Q · filed 2026-07-31 | $218.50M derived: sum of 3 quarters · filed 2026-07-31 | $348.30M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $7.90M 10-Q · filed 2026-05-05 | $111.00M derived: sum of 2 quarters · filed 2026-05-05 | $240.80M derived: sum of 3 quarters · filed 2026-05-05 | $305.80M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $103.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $232.90M derived: sum of 2 quarters · filed 2026-02-11 | $297.90M derived: sum of 3 quarters · filed 2026-02-11 | $341.30M 10-K · filed 2026-02-11 |
| 2024-09-30 | $129.80M 10-Q · filed 2025-10-28 | $194.80M derived: sum of 2 quarters · filed 2025-10-28 | $238.20M 10-Q · filed 2025-10-28 | $385.90M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $65.00M 10-Q · filed 2025-07-30 | $108.40M 10-Q · filed 2025-07-30 | $256.10M derived: sum of 3 quarters · filed 2026-02-11 | $339.20M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $43.40M 10-Q · filed 2025-05-05 | $191.10M derived: sum of 2 quarters · filed 2026-02-11 | $274.20M derived: sum of 3 quarters · filed 2026-02-11 | $369.70M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $147.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $230.80M derived: sum of 2 quarters · filed 2026-02-11 | $326.30M derived: sum of 3 quarters · filed 2026-02-11 | $249.70M 10-K · filed 2026-02-11 |
| 2023-09-30 | $83.10M 10-Q · filed 2024-10-30 | $178.60M derived: sum of 2 quarters · filed 2024-10-30 | $102.00M 10-Q · filed 2024-10-30 | $191.00M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $95.50M 10-Q · filed 2024-08-01 | $18.90M 10-Q · filed 2024-08-01 | $107.90M derived: sum of 3 quarters · filed 2025-02-10 | $176.40M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | -$76.60M 10-Q · filed 2024-05-01 | $12.40M derived: sum of 2 quarters · filed 2025-02-10 | $80.90M derived: sum of 3 quarters · filed 2025-02-10 | $64.00M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $89.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $157.50M derived: sum of 2 quarters · filed 2025-02-10 | $140.60M derived: sum of 3 quarters · filed 2025-02-10 | $154.50M 10-K · filed 2025-02-10 |
| 2022-09-30 | $68.50M 10-Q · filed 2023-10-31 | $51.60M derived: sum of 2 quarters · filed 2023-10-31 | $65.50M 10-Q · filed 2023-10-31 | $58.20M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | -$16.90M 10-Q · filed 2023-08-01 | -$3.00M 10-Q · filed 2023-08-01 | -$10.30M derived: sum of 3 quarters · filed 2024-02-09 | $12.20M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $13.90M 10-Q · filed 2023-05-03 | $6.60M derived: sum of 2 quarters · filed 2024-02-09 | $29.10M derived: sum of 3 quarters · filed 2024-02-09 | $71.40M derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | -$7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $15.20M derived: sum of 2 quarters · filed 2024-02-09 | $57.50M derived: sum of 3 quarters · filed 2024-02-09 | $89.60M 10-K · filed 2024-02-09 |
| 2021-09-30 | $22.50M 10-Q · filed 2022-11-01 | $64.80M derived: sum of 2 quarters · filed 2022-11-01 | $96.90M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $42.30M 10-Q · filed 2022-08-04 | $74.40M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $407.30M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |